BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND Ki-67 AND Treatment
294 results:

  • 1. Self-assembled nanomicelles for oral delivery of luteolin utilizing the intestinal lymphatic pathway to target pancreatic cancer.
    Karole A; Dinakar YH; Sagar P; Mudavath SL
    Nanoscale; 2024 Apr; 16(15):7453-7466. PubMed ID: 38517408
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
    Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
    Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
    Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
    BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.
    Perrier M; Brugel M; Gérard L; Goichot B; Lièvre A; Lepage C; Hautefeuille V; Do Cao C; Smith D; Thuillier P; Cros J; Cadiot G; Walter T; de Mestier L
    Eur J Endocrinol; 2023 Dec; 189(6):575-583. PubMed ID: 38039101
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
    Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
    Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Radiomics in CT and MR imaging of the liver and pancreas: tools with potential for clinical application.
    Berbís MÁ; Godino FP; Rodríguez-Comas J; Nava E; García-Figueiras R; Baleato-González S; Luna A
    Abdom Radiol (NY); 2024 Jan; 49(1):322-340. PubMed ID: 37889265
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Morken S; Langer SW; Sundlöv A; Vestermark LW; Ladekarl M; Hjortland GO; Svensson JB; Tabaksblat EM; Haslerud TM; Assmus J; Detlefsen S; Couvelard A; Perren A; Sorbye H
    Br J Cancer; 2023 Dec; 129(12):1930-1939. PubMed ID: 37872405
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
    Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
    Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma.
    Koh Y; Kim H; Joo SY; Song S; Choi YH; Kim HR; Moon B; Byun J; Hong J; Shin DY; Park S; Lee KH; Lee KT; Lee JK; Park D; Lee SH; Jang JY; Lee H; Kim JA; Yoon SS; Park JK
    J Transl Med; 2023 Oct; 21(1):730. PubMed ID: 37848935
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
    J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Local Sustained Chemotherapy of pancreatic cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel.
    Yang D; Ning J; Liao X; Jiang H; Qin S
    Int J Nanomedicine; 2023; 18():3989-4005. PubMed ID: 37496690
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.
    Sun T; Gilani S; Jain D; Cai G
    Diagn Cytopathol; 2023 Nov; 51(11):674-683. PubMed ID: 37469257
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Navale P; Chatterjee D; Itani M; Trikalinos NA
    Virchows Arch; 2023 Aug; 483(2):167-175. PubMed ID: 37354253
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
    Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
    Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. MGMT is frequently inactivated in pancreatic NET-G2 and is associated with the therapeutic activity of STZ-based regimens.
    Yagi K; Ono H; Kudo A; Kinowaki Y; Asano D; Watanabe S; Ishikawa Y; Ueda H; Akahoshi K; Tanaka S; Tanabe M
    Sci Rep; 2023 May; 13(1):7535. PubMed ID: 37161026
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Efficacy of endoscopic ultrasound-guided tissue acquisition for solid pancreatic lesions 20 mm or less in diameter suspected as neuroendocrine tumors or requiring differentiation.
    Kawasaki Y; Hijioka S; Nagashio Y; Maruki Y; Ohba A; Takeshita K; Takasaki T; Agarie D; Hagiwara Y; Hara H; Okamoto K; Yamashige D; Kondo S; Morizane C; Ueno H; Mizui T; Takamoto T; Nara S; Ban D; Esaki M; Tamada K; Hiraoka N; Saito Y; Okusaka T
    J Gastroenterol; 2023 Jul; 58(7):693-703. PubMed ID: 37154933
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effects of CCN6 overexpression on the cell motility and activation of p38/bone morphogenetic protein signaling pathways in pancreatic cancer cells.
    Nam MW; Lee HK; Kim CW; Choi Y; Ahn D; Go RE; Choi KC
    Biomed Pharmacother; 2023 Jul; 163():114780. PubMed ID: 37105075
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Characteristics and treatment results of patients with gastroenteropancreatic neuroendocrine tumors in a tertiary care centre.
    Bazarbashi S; Aseafan M; Elgazzar T; Alkhayat M; Alghabban A; Abdelgawad MI; Alshamsan B; Alshibany A; Elhassan T; Aljubran A; Alzahrani A; Alhindi H; Raef H
    BMC Endocr Disord; 2023 Apr; 23(1):74. PubMed ID: 37029347
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Evaluation of Survival Following Surgical Resection for Small Nonfunctional pancreatic Neuroendocrine Tumors.
    Sugawara T; Rodriguez Franco S; Kirsch MJ; Colborn KL; Ishida J; Grandi S; Al-Musawi MH; Gleisner A; Del Chiaro M; Schulick RD
    JAMA Netw Open; 2023 Mar; 6(3):e234096. PubMed ID: 36976561
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Can ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patients.
    Zerini D; Rotondi M; Volpe S; Pisa E; Frigo E; Pedone C; Flospergher M; Bagnardi V; Frassoni S; Fodor CI; Spada F; Fazio N; Alterio D; Jereczek-Fossa BA
    Tumori; 2023 Oct; 109(5):504-510. PubMed ID: 36942401
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 15.